Recent developments include expansion of the STARLIGHT-1 clinical trial, analyst buy recommendations, and financing activities.

• Estrella added a Cleveland site to its STARLIGHT-1 Phase I/II trial for B-cell lymphoma, indicating clinical trial expansion [N1].
• D. Boral Capital maintained a buy recommendation on Estrella Immunopharma, reflecting positive analyst sentiment [N2].
• D. Boral Capital initiated coverage of Estrella with a buy recommendation, highlighting market interest [N3].
• The company filed a $100 million common stock and warrants offering, supporting capital raising efforts [N4].
• Estrella was featured as one of three biotech stocks to watch for groundbreaking advances, indicating industry recognition [N5].

The company has advanced its STARLIGHT-1 clinical trial by adding new sites, indicating progress in clinical development. It has secured financing through stock and warrants offerings, supporting ongoing operations. Analyst coverage with buy recommendations reflects positive market interest. The leadership team's scientific and industry experience underpins the development of innovative cancer therapies. Estrella's compliance with Nasdaq listing standards and active investor communications contribute to transparency and governance.

Estrella reported a net loss and very limited cash and liquidity ratios as of June 30, 2026, indicating financial constraints. The current ratio of 0.2 and cash ratio of 0.01 suggest potential challenges in meeting short-term obligations. The company operates in a highly competitive and regulated biopharmaceutical sector with inherent risks in clinical development and commercialization. Dependence on successful clinical trial outcomes and additional financing poses execution risks. The company has disclosed risk factors that could materially affect its financial condition and results of operations.

Estrella's moat is based on its proprietary cancer immunotherapy drug candidates developed by a founder with significant scientific expertise and patent holdings. The company's focus on novel targets in oncology and its clinical-stage pipeline provide potential differentiation. The involvement of recognized scientific advisors and a specialized management team supports its technical capabilities. However, as a clinical-stage biopharmaceutical company, it faces typical industry risks including clinical trial outcomes, regulatory approvals, and capital requirements.

• Financial Liquidity Risk: As of June 30, 2026, Estrella had limited cash and a low current ratio, indicating potential challenges in meeting short-term liabilities.
• Clinical Development Risk: The success of Estrella's drug candidates depends on clinical trial outcomes, which are inherently uncertain and may impact future prospects.
• Regulatory and Market Risks: The company faces risks related to regulatory approvals, market acceptance, and competition in the oncology therapeutics space.

• Estrella Immunopharma, Inc. is a Delaware corporation headquartered in Emeryville, California.
• The company is listed on Nasdaq under ticker ESLA with common stock and warrants (ESLAW).
• Estrella is an emerging growth company as defined by SEC rules.
• The company is focused on biopharmaceutical development, specifically cancer immunotherapy, with clinical-stage drug candidates.
• The CEO and President is Dr. Cheng Liu, a founder with over 20 years of experience in antibody drug discovery and cancer immunotherapy, holding over 500 patents.
• The CFO is Peter Xu, with 15 years of experience in investment and management.
• The Board of Directors consists of seven members with diverse expertise in finance, medicine, technology, and management.
• Estrella has a scientific advisory board with experts in cancer immunotherapy and cell therapy.
• The company is conducting the STARLIGHT-1 Phase I/II clinical trial for EB103 targeting B-cell lymphoma.
• On January 5, 2026, Estrella entered into a securities purchase agreement for a registered direct offering and private placement involving common stock and warrants.
• The company filed a $100 million common stock and warrants offering in December 2024.
• As of June 30, 2026, Estrella had cash and cash equivalents of $100,000 and current assets of approximately $1.82 million, with current liabilities of about $9.26 million, resulting in a current ratio of 0.2 and a cash ratio of 0.01.
• The company reported a net loss of approximately $2.31 million for the quarter ended June 30, 2026, with basic and diluted EPS of -$0.05 per share.
• Estrella held its combined 2025/2026 annual meeting of stockholders virtually on June 29, 2026, with a quorum present.
• The company has regained compliance with Nasdaq listing requirements including minimum bid price as of September 2025.
• Risk factors disclosed in the 10-K and 10-Q filings include potential material adverse effects on results of operations or financial condition, with no material changes noted in the latest quarterly report.
• Recent news includes adding a Cleveland site to the STARLIGHT-1 trial, analyst buy recommendations, and financing activities.